Skip to content

13F-HR filed by Opaleye Management Inc.

Opaleye Management Inc. filed this 13F-HR for the quarter ended 2017-09-30, filed 2017-11-14, with 34 holding rows worth $282,715,000.

Accession
0001493152-17-013210
Filed
2017-11-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2017

A holdings report, 34 entries on the cover page, a total value of $282,715,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $282,772,000 with VALUE read as thousands by filing date, 13F file number 028-15896. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
BLUEPRINT MEDICINES CORP09627Y109COM735,000$51,207,000thousands by filing date
AXOGEN INC05463X106COM1,970,000$38,119,000thousands by filing date
FIBROGEN INC31572Q808COM360,000$19,368,000thousands by filing date
IMMUNOMEDICS INC452907108COM898,800$12,565,000thousands by filing date
LOXO ONCOLOGY INC548862101COM130,000$11,975,000thousands by filing date
CODEXIS INC192005106COM1,700,600$11,309,000thousands by filing date
CORIUM INTL INC21887L107COM920,000$10,193,000thousands by filing date
MOMENTA PHARMACEUTICALS INC60877T100COM500,000$9,250,000thousands by filing date
SANGAMO THERAPEUTICS INC800677106COM580,000$8,700,000thousands by filing date
AGIOS PHARMACEUTICALS INC00847X104COM130,000$8,677,000thousands by filing date
CYTOMX THERAPEUTICS INC23284F105COMMON STOCK450,000$8,176,000thousands by filing date
STRONGBRIDGE BIOPHARMA PLCG85347105SHS USD1,180,000$8,142,000thousands by filing date
EAGLE PHARMACEUTICALS INC269796108COM130,000$7,753,000thousands by filing date
CHIMERIX INC COM16934W106Stock1,403,000$7,365,000thousands by filing date
FOAMIX PHARMACEUTICALS LTDM46135105SHS1,142,000$6,338,000thousands by filing date
XOMA ROYALTY CORPORATION98419J206COMMON STOCK320,200$6,292,000thousands by filing date
THERAVANCE BIOPHARMA INCG8807B106COM180,000$6,163,000thousands by filing date
CYMABAY THERAPEUTICS INC23257D103COM665,000$5,356,000thousands by filing date
AUDENTES THERAPEUTICS INC.05070R104Common Stock180,000$5,041,000thousands by filing date
SYNLOGIC INC87166L100COM250,000$4,753,000thousands by filing date
ENANTA PHARMACEUTICALS INC29251M106COM100,000$4,680,000thousands by filing date
DECIPHERA PHARMACEUTICALS IN24344T101COM217,000$4,120,000thousands by filing date
ARDELYX INC039697107COM700,000$3,920,000thousands by filing date
ACCELERON PHARMA INC00434H108COM101,500$3,788,000thousands by filing date
INSMED INC COM PAR $.01457669307Stock120,000$3,745,000thousands by filing date
Rocket Pharmaceuticals Inc45780V102SHS1,802,000$3,207,000thousands by filing date
NEURODERM LTDM74231107ORD SHS70,000$2,723,000thousands by filing date
ARATANA THERAPEUTICS INC03874P101COM420,000$2,574,000thousands by filing date
SELECTA BIOSCIENCES INC816212104COM95,000$1,733,000thousands by filing date
SYROS PHARMACEUTICALS INC87184Q107COM116,574$1,716,000thousands by filing date
INTERCEPT PHARMACEUTICALS IN45845P108COM28,400$1,648,000thousands by filing date
ARQULE INC04269E107COM1,220,000$1,354,000thousands by filing date
QUOTIENT TECHNOLOGY INC749119103COMMON STOCK110,000$542,000thousands by filing date
BIOLINERX LTD-SPONS ADR09071M106SPON250,000$280,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001493152-17-013210this filing2017-11-14acceptance time not in the bulk data set